College of Pharmaceutical Sciences, The First Affiliated Hospital, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China.
Nucleic Acids Res. 2024 Jan 5;52(D1):D1450-D1464. doi: 10.1093/nar/gkad862.
Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial in the clinical development and clinical practice of all therapies. There are five types of ThMAR that have been found to play indispensable roles in various stages of drug discovery, such as: Pharmacodynamic Biomarker essential for guaranteeing the pharmacological effects of a therapy, Safety Biomarker critical for assessing the extent or likelihood of therapy-induced toxicity, Monitoring Biomarker indispensable for guiding clinical management by serially measuring patients' status, Predictive Biomarker crucial for maximizing the clinical outcome of a therapy for specific individuals, and Surrogate Endpoint fundamental for accelerating the approval of a therapy. However, these data of ThMARs has not been comprehensively described by any of the existing databases. Herein, a database, named 'TheMarker', was therefore constructed to (a) systematically offer all five types of ThMAR used at different stages of drug development, (b) comprehensively describe ThMAR information for the largest number of drugs among available databases, (c) extensively cover the widest disease classes by not just focusing on anticancer therapies. These data in TheMarker are expected to have great implication and significant impact on drug discovery and clinical practice, and it is freely accessible without any login requirement at: https://idrblab.org/themarker.
与传统的诊断/预后生物标志物（用作疾病状态/过程的指标）不同，治疗生物标志物（Therapeutic Biomarker，ThMAR）在所有治疗的临床开发和临床实践中变得非常关键。已经发现有五种类型的 ThMAR 在药物发现的各个阶段发挥着不可或缺的作用，例如：
然而，这些 ThMAR 的数据并没有被任何现有的数据库全面描述。因此，构建了一个名为“TheMarker”的数据库，以（a）系统地提供在药物开发的不同阶段使用的所有五种类型的 ThMAR；（b）在现有的数据库中全面描述 ThMAR 信息，涵盖数量最多的药物；（c）广泛涵盖最广泛的疾病类别，而不仅仅关注抗癌疗法。TheMarker 中的这些数据有望对药物发现和临床实践产生重大影响和重大影响，并且可以在无需登录的情况下免费访问：https://idrblab.org/themarker。
Nucleic Acids Res. 2024-1-5
Nucleic Acids Res. 2023-1-6
Nucleic Acids Res. 2022-1-7
Nucleic Acids Res. 2023-1-6
Cochrane Database Syst Rev. 2022-2-1
Nucleic Acids Res. 2021-1-8
Nucleic Acids Res. 2023-1-6
Nucleic Acids Res. 2024-1-5
J Cell Mol Med. 2025-8
Trends Pharmacol Sci. 2025-6
Nucleic Acids Res. 2025-7-7
Adv Sci (Weinh). 2025-4
Nucleic Acids Res. 2025-1-6
Nucleic Acids Res. 2025-1-6
Nucleic Acids Res. 2025-1-6
Neurooncol Adv. 2023-5-11
Proc Natl Acad Sci U S A. 2023-4-25
Nat Rev Drug Discov. 2023-4
Genomics Proteomics Bioinformatics. 2023-6
Database (Oxford). 2023-2-7
Nucleic Acids Res. 2023-1-6
Zotero 插件
